GAD-receptor Antibodies-associated Encephalitis
Conditions
Brief summary
Glutamic acid decarboxylase (GAD) is an enzyme whose function in the body is to decarboxylate glutamate to GABA. GAD65 antibodies (GAD65Ab) have been associated with type-1 diabetes (80% of new-onset patients) and various neurological conditions, mainly stiff-person syndrome (SPS/PERM), cerebellar ataxia (CA), limbic encephalitis (LE) and temporal lobe epilepsy. These syndromes all seem to result from a reduced transmission of GABA. These neurological conditions are rare and can cause symptoms like confusion, memory loss, muscle stiffness, muscle spasms, behavioural disorders, and pharmacoresistant epilepsy. When finding high levels of GAD65-Ab in the serum, a cerebrospinal fluid (CSF) sample should be taken to look for oligoclonal IgG bands and intrathecal GAD-Ab production to prove an auto-immune cause for the various neurological symptoms.
Interventions
OTHERGAD patients
Describe the clinical and demographic characteristics of patients with anti-GAD65 antibody associated cerebellar ataxia.
Sponsors
Hospices Civils de Lyon
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Inclusion criteria
* neurological symptoms with GAD antibody * GAD antibody in sera and/or CSF * patient with cerebellar ataxia
Exclusion criteria
* tested positive to another antibody. * no data * any test in paraneoplastic neurological syndrome and autoimmune encephalitis center
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| GAD Patient | Baseline | Description of clinical data in patients with cerebellar syndrome associated with anti-GAD antibodies |
Countries
France
Contacts
Primary ContactJérôme Honnorat, professor
Backup ContactMarine Villard, doctor
Outcome results
None listed